September 12, 2006 -- Valeant Pharma moved higher even though its hepatitis C drug did not meet all of its endpoints; Icagen rose after a safety committee recommended continuing a trial of its sickle cell drug; Arena Pharma began dosing patients in a Phase III obesity trial; Neurocrine released positive data from its Phase II trial of an endometriosis therapy; OXiGene will focus its ophthalmology efforts on an oral form of Combretastatin; Cerus began a Phase I trial of its Intercept red blood cell system; and Curis opened a subsidiary in Shanghai. The Centient Biotech 200™ climbed 29 points to 3713.18, a rise of .79%. More details...
